Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
Aleša Bricelj, Christian Steinebach, Robert D. Kuchta, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 158

Showing 26-50 of 158 citing articles:

Towards design of drugs and delivery systems with the Martini coarse-grained model
Lisbeth R. Kjølbye, Gilberto P. Pereira, Alessio Bartocci, et al.
QRB Discovery (2022) Vol. 3
Open Access | Times Cited: 28
Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
Chao Wang, Yujing Zhang, Lingyu Shi, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 1437-1453
Open Access | Times Cited: 27
Therapeutic Strategies to Target the Androgen Receptor
Weiguo Xiang, Shaomeng Wang
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8772-8797
Closed Access | Times Cited: 27
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
Pritam Maity, Joydeep Chatterjee, Kiran T. Patil, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3135-3172
Closed Access | Times Cited: 19
Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development
Mohd Danishuddin, Mohammad Sarwar Jamal, Kyoung Seob Song, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1649-1649
Open Access | Times Cited: 15
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation
Emily C. Erickson, Inchul You, Grace E. Perry, et al.
Science Signaling (2024) Vol. 17, Iss. 825
Open Access | Times Cited: 5
Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-Resistant Prostate Cancer
Hui Shen, Hongrui Xu, W. Q. Jin, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Auto-RapTAC: A Versatile and Sustainable Platform for the Automated Rapid Synthesis and Evaluation of PROTAC
Jiexuan Chen, Mingfei Wu, Jun Mo, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery of novel benzosultam CRBN ligands
Hoyeong Park, Santosh Shivanand Raikar, Yonghyo Kim, et al.
Bulletin of the Korean Chemical Society (2025)
Closed Access
Clozapine as an E3 Ligand for PROTAC Technology
Reina Takano, Nobumichi Ohoka, Takashi Kurohara, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 2, pp. 258-262
Closed Access
A patent review of von Hippel-Lindau (vhl)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present)
Aina Urbina, Alex J. Hallatt, Jack Robertson, et al.
Expert Opinion on Therapeutic Patents (2025), pp. 1-42
Closed Access
PROTAC technology for prostate cancer treatment
Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 1
Open Access
Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons
S.M. Ibrahim, Muhammad Umer Khan, Iqra Khurram, et al.
Food Science & Nutrition (2025) Vol. 13, Iss. 2
Open Access
A Comprehensive Primer and Review of PROTACs and Their In Silico Design
Jacopo Zattoni, Paola Vottero, Gea Carena, et al.
Computer Methods and Programs in Biomedicine (2025) Vol. 264, pp. 108687-108687
Open Access
PROTAC-induced protein structural dynamics in targeted protein degradation
Kingsley Y Wu, Ta I Hung, Chia‐en A. Chang
eLife (2025) Vol. 13
Open Access
Recent advances in the development of EGFR degraders: PROTACs and LYTACs
Dawei Hong, Bizhong Zhou, Bei Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 239, pp. 114533-114533
Closed Access | Times Cited: 26
Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
Qisi Zhang, Cyrille S. Kounde, Milon Mondal, et al.
Chemical Communications (2022) Vol. 58, Iss. 78, pp. 10933-10936
Open Access | Times Cited: 26
Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma
Muhammad Rishfi, Simon Krols, Fien Martens, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115033-115033
Open Access | Times Cited: 24
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines
Mikhail Krasavin, Maria Adamchik, Andrey Bubyrev, et al.
European Journal of Medicinal Chemistry (2022) Vol. 246, pp. 114990-114990
Closed Access | Times Cited: 23
PROTAC: targeted drug strategy. Principles and limitations
O. A. Koroleva, Yu. V. Dutikova, A.V. Trubnikov, et al.
Russian Chemical Bulletin (2022) Vol. 71, Iss. 11, pp. 2310-2334
Open Access | Times Cited: 22
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies
Bobby Lucero, Karol R. Francisco, Lawrence J. Liu, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 7, pp. 474-488
Open Access | Times Cited: 14
PROTACs Targeting MLKL Protect Cells from Necroptosis
Oliver H. Rathje, Lara Perryman, Richard J. Payne, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 11216-11236
Closed Access | Times Cited: 13
Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs
Christian Steinebach, Aleša Bricelj, Arunima Murgai, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14513-14543
Open Access | Times Cited: 13
Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release
Judith Bockstiegel, Silas Wurnig, Jonas Engelhardt, et al.
Biochemical Pharmacology (2023) Vol. 215, pp. 115693-115693
Closed Access | Times Cited: 12
Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders
Sarah F. Giardina, Elena Valdambrini, Pradeep K. Singh, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5473-5501
Closed Access | Times Cited: 4

Scroll to top